Health Cana­da is­sues two re­calls for Pfiz­er blood pres­sure drugs over im­pu­ri­ty

Last year, Pfiz­er stopped dis­tri­b­u­tion of megablock­buster smok­ing ces­sa­tion drug Chan­tix over an in­creased lev­el of car­cino­genic ni­trosamines.

Now, two of the Big Phar­ma’s blood pres­sure drugs have been re­called in Cana­da this week af­ter Cana­da’s health au­thor­i­ty found lev­els of a type of ni­trosamine too high to be al­lowed in the drugs.

Pfiz­er Cana­da re­called all 8 lots of blood pres­sure drug Ac­curet­ic yes­ter­day af­ter high­er-than-ap­proved lev­els of N-ni­troso-quinapril were found. That re­call was just two days af­ter the phar­ma sub­sidiary re­called 15 lots of In­der­al-LA, an­oth­er blood pres­sure drug, over sim­i­lar con­cerns over ni­trosamines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.